PSA change was defined as a PSA decline >50% from baseline at first radiological evaluation (after about 3 months from starting therapy) according to the Prostate Cancer Clinical Trials Working Group 3 guidelines. The gene discussed is KLK3; the disease is prostate carcinoma.